Medicine
Review Cycle Records
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy
Todd M. Morgan; Ching-Yu Wang; Halit O. Yapici; Jonathan Lilley; Weiqi Jiao; Kunal Lodaya; Haojie LiShow moreShow less
Department of Urology, University of Michigan, Ann Arbor, MI; Department of Outcomes Research, Merck & Co. Inc., Rahway, NJ; Department of Health Economics and Outcomes Research, Boston Strategic Partners Inc., Boston, MAShow moreShow less
Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer
Recep Eryılmaz; Muhammed Fatih Keleş; Rahmi Aslan; Zübeyir Huyut; Murat Demir; Kasım Ertaş; Mehmet Sevim; Kerem TakenShow moreShow less
Department of Urology, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Türkiye; Department of Biochemistry, Faculty of Medicine, Van Yüzüncü Yıl University, Van, Türkiye; Department of Urology, Van Training and Research Hospital, Van, Türkiye; Department of Urology, Akdamar Hospital, Van, TürkiyeShow moreShow less
Association of robot-assisted radical prostatectomy with improved oncological outcomes in patients with oligometastatic prostate cancer: A multicenter exploratory study in China
Yujie Dong; Zhen Tian; Weilin Chen; Zhuoran Li; Zhiqiang Chen; Jieping Hu; Bin Fu; Xiaofeng Xu; Xu Zhang; Baojun WangShow moreShow less
Senior Department of Urology, Chinese PLA General Hospital, Beijing, China; Department of Urology, The First Affiliated Hospital, Soochow Medical College, Soochow University, Soochow, Jiangsu, China; Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, ChinaShow moreShow less
The AURKA–PTTG1 signaling axis induces enzalutamide resistance in prostate cancer
Guangye Han; Zhenhui Li; Weihang Song; Lei Li; Junling HuShow moreShow less
Department of Urology, The First Affiliated Hospital of Henan Medical University, Xinxiang, Henan, ChinaShow moreShow less
Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis
James R. Janopaul-Naylor; Dattatraya Patil; Nikhil T. Sebastian; Kamran Salari; Bruce Hershatter; Christopher Gaffney; Martin G. Sanda; Shreyas S. Joshi; Pretesh R. Patel; Ashesh B. Jani; Sagar A. PatelShow moreShow less
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Urology, Emory University, Atlanta, GA; Department of Radiation Oncology, Emory University, Atlanta, GA; Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NYShow moreShow less
KDM6A suppresses proliferation and epithelial–mesenchymal transition in prostate cancer cells
Yixiu Ni; Yijia Lin; Wankun Wang; Yizhong Bao; Jun ChenShow moreShow less
Department of Urology, Affiliated Zhejiang Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaShow moreShow less
FAQ
How long does UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS take to review a manuscript?
As of 2026-11-19, CrushSCI has 15 complete review records for UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. The fastest paper went from submission to acceptance in 63 days (miR-638 Upregulation in Serum and Tissues Functions as a Diagnostic and Prognostic Biomarker and Facilitates Prostate Cancer Progression, received 2026-05-26, accepted 2026-07-28); the slowest took 252 days. The average is 120.6 days and the median is 124 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.